Trial Profile
An open phase II, multicentre study of ABR-214936 [anatumomab mafenatox] in patients with advanced renal cell carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2006
Price :
$35
*
At a glance
- Drugs Anatumomab mafenatox (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 05 May 2006 New trial record.